Please ensure Javascript is enabled for purposes of website accessibility

Here's 1 Short-Squeeze Stock That's Actually a Smart Pick to Buy and Hold

By Keith Speights - Feb 15, 2021 at 6:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The long-term prospects for this high-flying stock appear to be very good.

Short squeezes seem to have become something of a national pastime. Multiple heavily shorted stocks have skyrocketed this year, in large part because they were targeted by Reddit users looking for opportunities to make a lot of money very quickly.

Many of these stocks might have been lucrative to trade as short-sellers rushed to cover their positions. However, most of them aren't great picks for long-term investors. Their underlying business dynamics still aren't good despite their rising share prices.

There's at least one notable exception, though. Here's one short-squeeze stock that's actually a smart pick to buy and hold for the long term.

DNA with a light shining in the background

Image source: Getty Images.

Crushing it in COVID-19 testing 

Fulgent Genetics' (FLGT 3.03%) shares have more than tripled so far this year. Some of these gains have been the result of a short squeeze. Nearly 30% of Fulgent's float was sold short as of late January.

However, there's also another reason behind the healthcare stock's impressive performance. Fulgent has been absolutely crushing it with its COVID-19 testing products and services.

In 2020, Fulgent pivoted from its primary genetic testing products to focus on COVID-19 testing. In the third quarter of last year, it generated nearly $102 million in revenue, a whopping 880% year-over-year jump. Most of that growth came from its COVID-19 tests. 

The company's reverse transcription polymerase chain reaction (RT-PCR) COVID-19 test won emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA). Fulgent also offers a next-generation sequencing COVID-19 diagnostic test and an antibody test for lab use only. Physicians and healthcare facilities can even order a three-in-one test for diagnosing COVID-19, influenza A, and influenza B. In addition, Fulgent and Picture Genetics teamed up on an at-home COVID test.

Will Fulgent's COVID-19 revenue growth taper off? Sure. As more people are vaccinated, COVID-19 testing volumes will likely decline. However, the novel coronavirus won't go away. It will continue mutating, with new strains emerging. Fulgent will probably continue to generate solid revenue from COVID-19 testing for a long time to come. 

But wait -- there's more

Don't overlook the rest of Fulgent's business, though. In Q3, the company's non-COVID revenue soared 57% quarter-over-quarter. That's impressive growth in its own right. 

Fulgent initially focused on genetic testing for rare pediatric diseases. It then expanded into testing for cardiovascular and neurological disorders and for cancer. Today, the company offers a wide range of genomic testing. 

There are other players in the genomic testing market, of course. How can Fulgent win? The company has two primary competitive advantages. First, the flexibility of its technology enables Fulgent to quickly launch new products and services. Second, Fulgent boasts a market-leading cost structure.

Companies usually beat their rivals by either being better, faster, or cheaper. Fulgent checks off at least two of those boxes.

The long and short of it

It's possible (and perhaps even probable) that Fulgent's share price will pull back significantly this year as the euphoria from the COVID boom and the short squeeze wear off. Some Wall Street analysts practically hate the stock, with the average analysts price target only a little over half of Fulgent's current share price.

But the long-term potential for Fulgent is compelling. The global genetic testing market should reach $10 billion by 2022. That's just a start. Expect a ramp-up in consumer-driven genetic tests over the next few years. 

Even with the stock's huge run-up this year, Fulgent Genetics' market cap stands below $4 billion. Considering the company's total addressable market and its ability to execute, I think Fulgent could be worth a lot more by the end of this decade. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Fulgent Genetics, Inc. Stock Quote
Fulgent Genetics, Inc.
FLGT
$55.26 (3.03%) $1.62

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
338%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.